Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer

Our data do not support a correlation between topoisomerase II-α expression in breast cancer patients and improved clinical benefit with anthracycline therapy. However, they do suggest that tumors overexpressing topoisomerase II-α may experience better clinical benefit with higher anthracycline dose intensity.